The overall purpose of the Cell and Tissue Biology Core is to offer specialized services and reagents to Center members that are not readily available in their individual laboratories. Techniques such as primary liver cell culture and liver perfusion are complex and expensive; they cannot be performed without a very substantial investment in equipment and personnel training. Moreover, 20 years of experience have shown clearly that success is operator-dependent. Laboratories that perform these procedures on an occasional basis only are unlikely to achieve reproducible results. For example, when cell isolates are being prepared on a daily basis, as in the Core, small changes in quality are; readily detected and appropriate analysis is done. This is particularly important when new batches of reagents are introduced that may differ in key properties from those in current use. In this case, careful parallel testing is done to ensure that quality is maintained. Also, reagents such as enzymes for tissue dissociation have a limited shelf life. This is not an issue for a busy Core operation but can be important for the individual laboratory that performs the procedure on an occasional basis only. Thus, centralization of these services within a Core permits: (a) technology transfer to a broad range of Center investigators; (b) standardization of techniques with rigorous quality control; and (c) economy of scale. All of these enhance the productivity and efficiency of the Center as a whole. Another important mission of the Cell and Tissue Biology Core is to improve on existing techniques and develop new services as required by Center members. The history in this regard is noteworthy, as described above, and this remains a fundamental part of the Core?s mission and its service to Center investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK026743-21A1
Application #
6675388
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2002-09-30
Project End
2007-05-31
Budget Start
Budget End
Support Year
21
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Campos-Varela, Isabel; Agudelo, Eliana Z; Sarkar, Monika et al. (2018) Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis 20:
Dong, Mingjie; Liu, Xianqiong; Evert, Katja et al. (2018) Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis 9:31
Perito, Emily R; Bucuvalas, John; Lai, Jennifer C (2018) Functional status at listing predicts waitlist and posttransplant mortality in pediatric liver transplant candidates. Am J Transplant :
Marco-Rius, Irene; Gordon, Jeremy W; Mattis, Aras N et al. (2018) Diffusion-weighted imaging of hyperpolarized [13 C]urea in mouse liver. J Magn Reson Imaging 47:141-151
Takasaka, Naoki; Seed, Robert I; Cormier, Anthony et al. (2018) Integrin ?v?8-expressing tumor cells evade host immunity by regulating TGF-? activation in immune cells. JCI Insight 3:
von Morze, Cornelius; Tropp, James; Chen, Albert P et al. (2018) Sensitivity enhancement for detection of hyperpolarized 13 C MRI probes with 1 H spin coupling introduced by enzymatic transformation in vivo. Magn Reson Med 80:36-41
Lai, Jennifer C; Segev, Dorry L; McCulloch, Charles E et al. (2018) Physical frailty after liver transplantation. Am J Transplant 18:1986-1994
Kardashian, Ani A; Dodge, Jennifer L; Roberts, John et al. (2018) Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int 38:553-563
von Morze, Cornelius (2018) Detecting liver injury non-invasively using hyperpolarized 13 C MRI. Liver Int 38:988-990
Huang, Annsa C; Mehta, Neil; Dodge, Jennifer L et al. (2018) Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 68:449-461

Showing the most recent 10 out of 1119 publications